FDA Urged Reformation of PMTA Process

Regulations by 2FIRSTS.ai
Dec.18.2023
FDA Urged Reformation of PMTA Process
US senators urge the FDA's Center for Tobacco Products to reform the pre-market tobacco product application process.

According to a report from Vaporvoice, United States Senators Joe Manchin, Rand Paul, and Ted Budd have jointly written a letter to the Center for Tobacco Products (CTP) of the Food and Drug Administration (FDA), urging it to reform the pre-market tobacco product application (PMTA) process. Additionally, they have requested the center to provide information regarding policies and actions taken to ensure that its actions are grounded in science and evidence and conducted in an effective manner.

 

A report highlights that "smoking is a leading cause of preventable diseases and deaths in the United States, with approximately 31 million Americans being smokers," wrote the senators in their letter. "In order to achieve the Food and Drug Administration's goal of reducing harm, an effective authorization process must be in place.

 

Since 2009, more than 26 million PMTA applications for new products have been submitted in the United States. However, the Center for Tobacco Products (CTP) has only approved less than 50 of these applications. Senators argue that availability of scientifically backed and authorized PMTA or MRTP could potentially improve the health conditions of current smokers using risky tobacco products.

 

Senators mentioned that in order to achieve the goal of preventing harm to public health, the FDA must have an effective authorization process. Additionally, they also stated that the FDA's authorization speed is far from acknowledging the risk levels of tobacco products.

 

Senators wrote in a letter, "Previously, CTP attributed its backlog of work to staff shortage, but over the past decade, the number of employees at CTP has grown from 426 in 2013 to over 1,100 now.

 

According to them, since 2009, the FDA has had the authority to assess and collect user fees from tobacco manufacturers and importers, with these fees reaching $712 million per year since 2019. "With such substantial resources, there should be no reason for the CTP to be incapable of complying with the requirements of the Food, Drug, and Cosmetic Act.

 

Disclaimer: 
This article is translated from an original Chinese article available on 2firsts.cn by AI, and has been reviewed and edited by 2FIRSTS's English editorial team. The Chinese original text is the only authoritative source of information. The exclusive copyright and license rights to this article are held by 2FIRSTS Technology Co., Ltd. Any reproduction, reprinting, or redistribution of this article, either in part or in full, requires express written permission from 2FIRSTS and must include clear attribution along with a link to this content. Non-compliance may result in legal action. 2FIRSTS Technology Co., Ltd. reserves the right to pursue legal actions in case of unauthorized use or distribution.